Searchable abstracts of presentations at key conferences in endocrinology

ea0017p21 | (1) | BSPED2008

Premature sexual maturation: incidence and aetiology

Stanley S , Stone E , Kirk J

Over the last few years, we have seen increasing numbers of referrals to our regional paediatric endocrine unit with premature sexual maturation (PSM), especially adrenarche and isolated thelarche. Therefore, we audited referrals for PSM over three years, and compared them to published historical data collected over 15 years in another regional paediatric endocrine unit (Bridges et al. 1994).<thead valig...

ea0002p78 | Reproduction | SFE2001

Alternative splicing of 15-hydroxyprostaglandin dehydrogenase (PGDH) in human chorio-decidua, placenta and myometrium

Slater D , Kirk R , Bennett P

Prostaglandins are strongly implicated in the onset and maintenance of human parturition and their synthesis is increased within the uterus in association with labour. Enzymes involved in their synthesis, (cyclo-oxygenase-2), and catabolism, (prostaglandin dehydrogenase) are up and down-regulated respectively, in association with labour. The human prostaglandin dehydrogenase (PGDH) gene is approximately 34kb in size. A large 5' promoter region containing numerous potential tra...

ea0045p68 | Pituitary and growth | BSPED2016

Normal final height in late presenting girls with Turner Syndrome (TS)

Sakka Sophia , Shaw Nick , Kirk Jeremy

Introduction: The diagnosis of Turner Syndrome (TS) must be included in the differential diagnosis of all girls with short stature. Despite overall earlier diagnosisand treatment there remain patients with TS who present late with delayed puberty.Although growth hormone (GH) is known to increase final height (FH) in girls with TS, little evidence exists on treatment in late-presenting girls.Objective and hypothesis: To assess the effect of late GH treatm...

ea0036P70 | (1) | BSPED2014

Evaluating the diagnostic value of basal LH and LHRH test in predicting progression into precocious puberty in girls

Hu Kun , Kirk Lucinder , Sandhu Karam , Odubiyi Oreoluwa , Kirk Jeremy , Shaw Nick

Introduction: Current recommendations for diagnosing central precocious puberty (CPP) in girls suggest using basal LH levels >0.3 IU/l to predict progression into CPP and using stimulated LH values >5 IU/l in the LHRH test to diagnose CPP. Our objectives were to test the efficacy of using basal LH values as well as to establish diagnostic cut-offs for LHRH tests.Method: Retrospective data collection of LHRH test results of 173 girls between 2 and...

ea0039ep104 | Pituitary and growth | BSPED2015

Overcoming the need for a second test: an evaluation of anthropometric, biochemical, and radiological parameters in the diagnosis of GH deficiency

Ali Muzzammil , Casey Angela , Kirk Jeremy , Dias Renuka

Background: The investigation of short stature includes evaluation of a number of clinical, radiological, and biochemical factors. This often includes dynamic function testing to rule out abnormalities of the hypothalamic–pituitary axis to rule out GH deficiency (GHD). NICE guidance advises that two GH stimulation tests demonstrating subnormal GH peak <6.7 μg/ml (20 mU/l) is required to confirm the diagnosis of GHD.Objectives: To interrogat...

ea0039ep113 | Pituitary and growth | BSPED2015

Endocrine outcomes in hypothalamic hamartoma: a single-centre study

Fan Hui , Shaw Nicholas , Barrett Timothy , Kirk Jeremy , Dias Renuka

Background: Hypothalamic hamartomas (HH) are congenital, benign tumours consisting of disorganised neuronal cells within the hypothalamus. They usually present with precocious puberty, seizures, behavioural abnormalities, either in isolation or combined.Aims: To look at the endocrine outcomes of patients with HH.Methods: A retrospective casenote review of all patients diagnosed with HH over a 20-year period within a single endocrin...

ea0033oc1.1 | Oral Communications 1 | BSPED2013

GH testing: reducing the need for a second test for the diagnosis of GH deficiency

Juma Zain , Casey Angela , Prior Jullia , Kirk Jeremy , Dias Renuka

Background: The diagnosis of isolated GH deficiency (IGHD) is based on multiple factors: clinical, radiological and biochemical along with suboptimal peak GH levels demonstrated on dynamic testing. Recent guidance from the National Institute of Clinical Excellence (NICE; UK; 2010) advises that two GH stimulation tests must demonstrate a subnormal GH peak <6.7 μg/l (20 mU/l) to confirm the diagnosis of IGHD. In our centre, three different GH provocation tests are used:...

ea0033p70 | (1) | BSPED2013

Growth hormone device change-over; is it beneficial?

Ayuk Loveline , Casey Angela , Prior Julia , Kirk Jeremy

Recombinant growth hormone (GH) administration uses several different injection devices. Despite offering free patient choice at GH therapy start, ~20% of our patients subsequently change GH device.Objective: To investigate reasons for GH device change, and evaluate the effect on adherence, height velocity standard deviation (HVSDS), and insulin-like growth factor-1 (IGF1).Method: Retrospective study of extracted growth data and la...

ea0027p16 | (1) | BSPED2011

GH stimulation testing: how discrepant are its diagnostic tests?

Bhat Gayathri , Knight Olivia , Barrett Timothy , Kirk Jeremy

As the sensitivity of a single GH test is poor, current NICE guidelines (2010) state that to make a diagnosis of isolated GH deficiency (IGHD), two stimulation tests need to show subnormal peak GH levels. In our centre we use insulin tolerance (ITT) or glucagon stimulation (GST) as the 1st test, and arginine stimulation (AST) as the 2nd test.The purpose of this study was to identify the proportion of children with discrepant test results; and to establis...

ea0017p2 | (1) | BSPED2008

Optic nerve hypoplasia in patients with septo optic dysplasia (SOD) and isolated optic nerve hypoplasia (ONH)

Stone E , Kirk J , Willshaw H , Goode P

Introduction: Optic nerve hypoplasia (ONH) can be bilateral or unilateral. It may be found either as an isolated finding or as part of other conditions such as septo-optic dysplasia (SOD), a variable triad of ONH, midline brain defects, and hypopituitarism. We have analysed data on patients with ONH within our regional cohort.Patients and methods: Ophthalmology and endocrinology case records from 136 patients with SOD (56) or ONH (79) were analysed. ONH ...